Germany
-
Fresenius partners with WuXi Biologics to expand biosimilar pipeline to 66 molecules
The collaboration will initially focus on biosimilar versions of Roche’s cancer treatment Polivy and Amgen’s thyroid eye disease therapy Tepezza.
-
Siemens Healthineers showcases Cios Go Mobile C-arm Platform at German Orthopedic Congress
The Cios Go ID addresses these challenges with a compact design and an integrated touchscreen display that clinicians can position according to their needs.
-
Roche secures global rights to Alector’s Parkinson’s drug candidate in US$1.27B deal
Under the agreement, Roche’s Genentech subsidiary will oversee development, regulatory activities, manufacturing and commercialisation across all indications.
-
Sanner Group appoints Frank Bamberg as COO to strengthen global manufacturing operations
Bamberg brings more than 20 years of international experience in regulated manufacturing, with expertise spanning medical devices, combination products and pharmaceutical production.
-
BioNTech to close three German sites after failed sale efforts
The Mainz-based biopharmaceutical company said the closures will affect about 1,800 employees at sites in Tübingen, Marburg and Idar-Oberstein.
-
Siemens Healthineers launches INNOVANCE D-Dimer 2.0 globally to support VTE assessment
D-dimer testing measures fragments produced when blood clots break down and can help assess patients with increased clotting activity.
-
Siemens Healthineers launches Accela radiotherapy platform in Germany
The development of Accela and NeoArc involved collaboration with an advisory group comprising several cancer research and treatment institutions.
-
Boehringer Ingelheim partners with Envisagenics to identify precision cancer targets in 2026
The collaboration will assess selected targets for several therapeutic approaches, including antibody-drug conjugates (ADCs), multispecific antibodies and T cell engagers (TcEs).
-
Roche strikes US$1B bispecific antibody discovery deal with Dualitas Therapeutics
Roche will take responsibility for subsequent development activities, including preclinical research, and oversee the programmes as they progress towards potential commercialisation.
-
GSK to close German flu vaccine plant as demand for egg-based shots falls
The shift also comes as pharmaceutical companies invest in newer technologies that could change how influenza vaccines are developed and manufactured.